Reports
Sale
Global Neurology Clinical Trials Market Size, Trends, Report: By Type: Phase I, Phase II, Phase III, Phase IV; By Indications: Epilepsy, Stroke, Alzheimer's Disease (AD), Parkinson's Disease (PD), Others; By Study Design: Interventional, Observational, Expanded Access; Regional Analysis; Competitive Landscape; 2024-2032
Global Neurology Clinical Trials Market Outlook
The global neurology clinical trials market size was valued at USD 5.7 billion in 2023, driven by increasing technological innovations across the globe. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 to achieve a value of USD 9.4 billion by 2032.
Neurology Clinical Trials: Introduction
Neurology clinical trials are research studies that assess medical, surgical, or behavioral intervention in people related to diseases and disorders associated with brain or cognitive behavior. These trials are among the primary approaches that are used by the researchers to determine if a new treatment or prevention, such as a new drug, diet, or medical device, is safe to use and effective in people. A neurology clinical trial is mostly designed to learn if a new treatment is more effective or has fewer harmful side effects than existing treatments associated with it.
Neurology diseases are becoming more common around the world, with conditions such as epilepsy, Alzheimer's and other forms of dementia, strokes, migraines, multiple sclerosis, Parkinson's disease, neurological infections, brain tumors, or any other issue in nervous system. As a result, there has been a rise in the number of clinical trials being conducted to find treatments for these conditions, emphasizing the importance of addressing these diseases as soon as possible.
Global Neurology Clinical Trials Market Analysis
The market has been witnessing significant growth due to the increasing number of neurology clinical trials. For example, a new groundbreaking trial has been conducted at the UCL (University College London) and UCLH (University College London Hospitals). This trial is one of its kind and has found a new genetic therapy for Alzheimer’s disease that assists patients in recovering from the disease by lowering the levels of the harmful protein responsible for it, known as the Tau Protein. Such clinical trials are expected to further escalate the neurology clinical trials market growth as the demand for new therapeutic approaches and personalized treatments is continuously on the rise.
Moreover, the market growth is driven by the continuous expansion of decentralized trial models. Decentralized trials are remote trials that provide added flexibility and patient-centered study designs facilitating the collection of data from patients remotely in real-time. Participation in clinical trials with the use of advanced technologies like telemedicine, remote monitoring, and electronic consent has become easier for patients without needing to visit the trial site physically.
Global Neurology Clinical Trials Market Segmentations
Market Breakup by Type
- Phase I
- Phase II
- Phase III
- Phase IV
Market Breakup by Indications
- Epilepsy
- Stroke
- Alzheimer's Disease (AD)
- Parkinson's Disease (PD)
- Others
Market Breakup by Study Design
- Interventional
- Observational
- Expanded Access
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Neurology Clinical Trials Market Overview
Neurological diseases are among the most common causes of the rising mortality rate in the geriatric population. Most people with dementia are diagnosed with one or more chronic health conditions in their lifetime. The major reason for this is the increasing number of neurological diseases, such as dementia, stroke, and peripheral neuropathy. The market growth is driven by the growing research and development investments in neurological research activities. Rising government funding for neurological research is also anticipated to contribute to the neurology clinical trials market growth. Major pharmaceutical companies are focusing on conducting clinical trials in neurology to find and improve new treatment approaches for neurological disorders and diseases resulting in patient outcomes. The market is simultaneously driven by the increasing prevalence of various neurological diseases.
North America has been dominating the global market owing to the rising prevalence of neurological disorders and the presence of major market players in clinical trials. The market growth is also driven by the increasing number of geriatric patients with dementia exemplified by the estimate that nearly 8.4 million people in the region aged 65 and older are expected to be suffering from Alzheimer's disease or another dementia by 2030.
Global Neurology Clinical Trials Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Supernus Pharmaceuticals, Inc.
- AstraZeneca
- Aurobindo Pharma
- Eisai Co., Ltd.
- Eli Lilly and Company
- Aurora Health Care
- AbbVie Inc.
- Zydus Group
- Athira Pharma, Inc.
- Annovis Bio
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indications |
|
| Breakup by Study Design |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Neurology Clinical Trials Market Overview
3.1 Global Neurology Clinical Trials Market Historical Value (2017-2023)
3.2 Global Neurology Clinical Trials Market Forecast Value (2024-2032)
4 Global Neurology Clinical Trials Market Landscape
4.1 Global Neurology Clinical Trials: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Neurology Clinical Trials: Product Landscape
4.2.1 Analysis by Phase
4.2.2 Analysis by Indications
5 Global Neurology Clinical Trials Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Neurology Clinical Trials Market Segmentation
6.1 Global Neurology Clinical Trials Market by Type
6.1.1 Market Overview
6.1.2 Phase I
6.1.3 Phase II
6.1.4 Phase III
6.1.5 Phase IV
6.2 Global Neurology Clinical Trials Market by Indications
6.2.1 Market Overview
6.2.2 Epilepsy
6.2.3 Stroke
6.2.4 Alzheimer's Disease (AD)
6.2.5 Parkinson's Disease (PD)
6.2.6 Others
6.3 Global Neurology Clinical Trials Market by Study Design
6.3.1 Market Overview
6.3.2 Interventional
6.3.3 Observational
6.3.4 Expanded Access
6.4 Global Neurology Clinical Trials Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Neurology Clinical Trials Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Neurology Clinical Trials Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Neurology Clinical Trials Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Neurology Clinical Trials Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Neurology Clinical Trials Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Supernus Pharmaceuticals, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 AstraZeneca
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Aurobindo Pharma
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Eisai Co., Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Eli Lilly and Company
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Aurora Health Care
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 AbbVie Inc.
17.7.1 Product Portfolio
17.7.2 Demographic Reach and Achievements
17.7.3 Mergers and Acquisitions
17.7.4 Certifications
17.8 Zydus Group
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Athira Pharma, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Annovis Bio
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 5.7 billion in 2023, driven by the increasing number of neurological diseases.
The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 9.4 billion by 2032.
The growth of the market is primarily driven by the rising prevalence of neurological diseases and disorders like epilepsy and dementia. Other factors aiding the market growth include the rising healthcare sector and the rising demand for improved treatments.
The increasing investments in research and development activities related to neurological diseases is a major trend influencing the market growth.
The major regional markets include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Different types in the market include Phase I, Phase II, Phase III, and Phase IV.
Various indications include epilepsy, stroke, Alzheimer’s disease (AD), and Parkinson’s disease (PD), among others.
Various study designs include interventional, observational, and expanded access.
Key players involved in the market are Supernus Pharmaceuticals, Inc., AstraZeneca, Aurobindo Pharma, Eisai Co., Ltd., Eli Lilly and Company, Aurora Health Care, AbbVie Inc., Zydus Group, Athira Pharma, Inc., and Annovis Bio.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER